From a therapeutic perspective, we have provided an alternative strategy for targeting cancer therapeutics by using the FAK/25aa peptide to inhibit β4 integrin/FAK complex formation in triple-negative breast cancers (Figs 4 and 5 and our unpublished data). The gene discussed is PTK2; the disease is triple-negative breast carcinoma.